Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcutis Biotherapeutics (ARQT) Change in Inventory: 2022-2025

Historic Change in Inventory for Arcutis Biotherapeutics (ARQT) over the last 3 years, with Sep 2025 value amounting to $5.9 million.

  • Arcutis Biotherapeutics' Change in Inventory rose 1064.16% to $5.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.6 million, marking a year-over-year increase of 1278.42%. This contributed to the annual value of $400,000 for FY2024, which is 92.88% down from last year.
  • According to the latest figures from Q3 2025, Arcutis Biotherapeutics' Change in Inventory is $5.9 million, which was up 1,237.26% from -$518,000 recorded in Q2 2025.
  • In the past 5 years, Arcutis Biotherapeutics' Change in Inventory ranged from a high of $5.9 million in Q3 2025 and a low of -$779,000 during Q4 2023.
  • Moreover, its 3-year median value for Change in Inventory was $633,000 (2024), whereas its average is $1.2 million.
  • Over the last 5 years, Arcutis Biotherapeutics' Change in Inventory had its largest YoY gain of 1,626.55% in 2025, and its largest YoY loss of 181.83% in 2025.
  • Over the past 4 years, Arcutis Biotherapeutics' Change in Inventory (Quarterly) stood at $3.2 million in 2022, then plummeted by 124.29% to -$779,000 in 2023, then spiked by 134.02% to $265,000 in 2024, then soared by 1,064.16% to $5.9 million in 2025.
  • Its Change in Inventory stands at $5.9 million for Q3 2025, versus -$518,000 for Q2 2025 and $2.0 million for Q1 2025.